Latest data on SGLT2is in heart failure | With Prof. Javed Butler

Diabetes Knowledge into Practice Podcast

In late 2020, we published an episode looking at the management of diabetes and heart failure when both present together. Since then, a wealth of evidence has been published on the effects of sodium glucose cotransporter type 2 (SGLT2) inhibitors in people with heart failure with or without type 2 diabetes. These findings have led to expanded indications for some of these agents to include heart failure. Today we will examine these data and their relevance in clinical practice in the setting of type 2 diabetes with heart failure.

Joining us to discuss what these data mean for clinical practice is Prof. Javed Butler, who is Professor and Chairman of the Department of Medicine at the University of Mississippi Medical Centre in Jackson, Mississippi.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Javed Butler declares the following:

Consultant: Abbott, Adrenomed, Amgen, Applied Therapeutics, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharma, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sequana Medical, and Vifor

Speakers Bureaus: Novartis, Boehringer Ingelheim-Lilly, Astra Zeneca, Janssen

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Funding:

This independent educational activity is supported by an educational grant from Eli Lilly. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Eli Lilly has had no influence on the content of this education.